Advancing Innovative Medicines to Target Metabolic Heath and Neurological Diseases
The Power of the Gut-Brain Axis
Our lead program, BL-001, is a live biotherapeutic product reverse engineered to replicate the ketogenic diet’s clinical efficacy. BL-001 has demonstrated proof of mechanism and has been observed to be safe and tolerable, with Bloom planning Phase 2 clinical trials in both obesity and Dravet syndrome.
The IrisRx™ discovery platform powers Bloom’s pipeline by integrating cutting-edge science and a proprietary knowledgebase. This platform enables the development of novel, multi-pathway therapeutics through gut commensal microbes and synthetic biology, delivering innovative treatments with broad therapeutic potential.
Pioneering a New Class of Treatments
Bloom Science is redefining medicine by creating innovative therapies that harness the body’s natural metabolic and neurological pathways. Inspired by the therapeutic benefits of the ketogenic diet, Bloom’s approach targets multiple mechanisms simultaneously to provide safer, more effective solutions for obesity, Dravet syndrome, ALS, and other complex conditions.
Inspired by the therapeutic benefits of the ketogenic diet
Leadership
We are a team of passionate and committed scientists, data-geeks, advocates, and entrepreneurs developing first-in-class, breakthrough therapeutics that target metabolic health and the Gut-Brain Axis. Our goal is to transform the quality of life of patients and their families with unmet needs.
Partners
We are interested in collaborators who share our vision and goals, and whose capabilities complement our best-in-class drug discovery platform and development team.
Careers
At Bloom, we are seeking innovative, passionate, and motivated team players- committed to changing the way we treat disease through groundbreaking science. We have built a team with extensive scientific, business, clinical and leadership backgrounds.
News
Bloom Science to Present at the Biocom Global Partnering & Investor Conference
SAN DIEGO, Calif., February 20, 2024 — Bloom Science, Inc., today announced that Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science, will be presenting at the Biocom Global Partnering & Investor Conference being held February 27-29, 2024 at the...
Bloom Science Granted Multiple New US and EU Patents Strengthening its IP Portfolio
SAN DIEGO, Calif., January 31, 2024 —Bloom Science, Inc., today announced that the United States Patent and Trademark Office (USPTO) and European Patent Office have issued multiple new patents, US 11,883,441 and EP 3558329 (covering 18 countries). The new patents...
Bloom Science to Present at the 7th Annual Sachs Neuroscience Innovation Forum
SAN DIEGO, Calif., January 2, 2024 - Bloom Science, Inc., today announced that Christopher Reyes, Ph.D., Chief Executive Officer of Bloom Science, will be presenting at the 7th Annual Sachs Neuroscience Innovation Forum being held January 7, 2024 at the Marines’...